Latest Breaking News On - Arsenic trioxide - Page 1 : comparemela.com

Arsenic trioxide_Leading local media on chemical materials, nano-ma

Arsenic trioxide_Leading local media on chemical materials, nano-ma
mis-asia.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from mis-asia.com Daily Mail and Mail on Sunday newspapers.

Arsenic trioxide

All-Oral Arsenic Trioxide, All-Trans Retinoic Acid/Ascorbic Acid Proves Effective, Safe in Acute Promyelocytic Leukemia

Treatment with an all-oral regimen of arsenic trioxide, all-trans retinoic acid, and ascorbic acid led to both 3-year overall survival and relapse-free survival rates of 97% in patients with acute promyelocytic leukemia.

Harinder gillSchool of clinical medicineDepartment of medicineUniversity of hong kongClinical medicineHong kongArsenic trioxideRetinoic acidAbsorbic acid2023 ash annual meetingAcute promyelocytic leukemia

BioSenic on its way to find the necessary funds to perform its key clinical trial on chronic Graft-versus-Host Disease

PRESS RELEASE – INSIDE INFORMATION Biosenic signs term sheet with SPRIM Global Investments (TrialCap fund) for up to USD 8 million debt financing and USD 800,000 equity investment as a first decisive, financing step towards a Phase 3 clinical trial for its ground-breaking auto-immune medication, a first-in-class drug oral arsenic salt. Mont-Saint-Guibert, Belgium, December 6, 2023, 7.00 am CEST – BIOSENIC (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious aut

Mont saint guibertWaals gewestScience parkSingapore generalFrance generalTrialcap pteGhislaine gasparettoNeil hunter michelle boxallInternational media enquiriesTrialcap fundRd serviceClinical research organizationGlobal investment companyIb communicationsEuronext brusselsTerm sheet

BioSenic provides third quarter 2023 Business Update

REGULATED INFORMATION Following the in-principle agreement reached with its main creditors in the context of ongoing equity raise process, the focus of BioSenic is now to proceed with fundraising, allowing to start its phase 3 international clinical trial with oral arsenic trioxide (ATO) in the first-line treatment of chronic Graft-versus-Host-Disease (cGvHD). Mont-Saint-Guibert, Belgium, October 25, 2023, 7.00 am CEST – BioSenic provides third quarter 2023 Business Update Following the in-princ

France generalMont saint guibertWaals gewestNeil hunter michelle boxallSeitosei actifinMedsenic biosenicGhislaine gasparettoBiosenic groupIb communicationsEuropean patent officeEuropean investment bankInternational media enquiriesNeither the companyArthritis research therapyChina national intellectual property administrationEuronext brussels

BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD

BioSenic performs further analysis of its phase 2 clinical trial data, leading to an optimal administration scheme for its next late-stage trial of arsenic trioxide in cGvHD New post-hoc analysis.

Mont saint guibertWaals gewestFrance generalSeitosei actifinGhislaine gasparettoNeil hunter michelle boxallNeither the companyInternational media enquiriesIb communicationsEuronext brusselsChronic graft versus host diseaseArsenic trioxideCellular therapyHigh response rateArsenic trioxide based first line therapyAllogeneic hematopoietic stem cell